Severe Inflammatory Acne Vulgaris
Highly investigational use for severe nodulocystic acne refractory to isotretinoin; very limited anecdotal evidence and significant scarring risk concerns.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for acne. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for nodulocystic acne is investigational and considered exploratory.
- Какие доказательства существуют?
- Tier C (investigational). Only anecdotal case reports without standardized acne severity grading; there are no randomized controlled trials. Evidence-based therapy for severe inflammatory nodulocystic acne is isotretinoin (95 percent response rate), with adjunctive doxycycline, hormonal therapy (combined oral contraceptives, spironolactone in women), and topical retinoids. AAD guidelines establish isotretinoin as standard. The risk-benefit ratio of leech therapy is unfavorable in most patients given scarring risk.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Significant post-inflammatory hyperpigmentation, especially in Fitzpatrick IV-VI skin
- Permanent scarring or new acne-scar formation at bite sites
- Worsening of cystic acne if leech placed on cyst centers
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Drug-leech interaction unknown if on isotretinoin (bleeding risk theoretical)
- Delay of evidence-based isotretinoin or hormonal therapy
- Кому не следует это рассматривать
- Patients currently on isotretinoin therapy (bleeding-risk interaction unknown)
- Patients with prior keloid or hypertrophic scarring tendency
- Patients with acne fulminans (systemic corticosteroid emergency)
- Patients with darker Fitzpatrick skin types at high PIH risk
- Patients on anticoagulants or with severe anemia
- Patients who have not been offered isotretinoin by a dermatologist
- О чём спросить врача
- Have I tried isotretinoin, or do I have a contraindication?
- What is the realistic risk that bite sites will scar or hyperpigment given my skin type?
- What evidence supports leech therapy for severe acne specifically?
- Will placement be on intact skin adjacent to nodules, never on the cyst itself?
- Are leeches from an FDA-registered supplier and used only once?
- What is the Aeromonas-prevention plan?
- What is the cost and is it covered by insurance? (typically not covered)
- Когда срочно обратиться за медицинской помощью
- Sudden rapid worsening with fever, severe joint pain, and ulcerating nodules (acne fulminans — emergency)
- Spreading redness, warmth, pus, or red streaks (cellulitis or abscess)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Severe bleeding combined with isotretinoin use (rare but possible)
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Что это НЕ означает
- This is NOT FDA-cleared for acne vulgaris.
- Anecdotal case reports do NOT establish efficacy versus isotretinoin, the gold-standard treatment.
- It does NOT mean leech therapy is safe in patients prone to scarring or hyperpigmentation — risks may outweigh benefits.
- It does NOT mean cystic acne should be treated by anyone other than a dermatologist with full pharmacologic options.
- It does NOT substitute for isotretinoin, hormonal therapy, or topical retinoids in evidence-based regimens.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- dermatological
- ICD-10
- L70.0, L70.1, L70.8, L70.9
- Safety tier
- high
Evidence Summary
Severe inflammatory (nodulocystic) acne vulgaris is conventionally treated with isotretinoin (high response rate) and adjunctive antibiotics or hormonal therapy. There is no clinical trial or efficacy case series supporting leech therapy for acne; the only leech-related report in this context describes a serious adverse event (hemorrhagic complication after a leech bite). Leech application also carries a significant risk of post-leech-site hyperpigmentation and scarring that could worsen cosmetic outcomes. Evidence is grade D and the risk-benefit ratio is unfavorable for most patients. Isotretinoin completion (with appropriate monitoring) remains the standard of care.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Karne SS et al. (2019)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active isotretinoin therapy (drug-leech interaction unknown; bleeding risk)
- Prior keloid or hypertrophic scarring tendency
- Acne fulminans (systemic corticosteroid emergent)
- Patients with darker Fitzpatrick skin types at high PIH risk
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.